





Characterization of mAbs Using RP Separations and High Resolution Accurate Mass (HRAM) Mass Spectrometry

2016 Pharma Tour

Antibody Therapeutics – An Analytical Challenge



Characterization

- to ensure proper biomanufacturing of the therapeutics
- to ensure critical quality attributes (CQA's) of a product are identified
Modifications, impurities, immunogenicity, efficacy, DMPK
- to ensure these CQA's can be routinely measured
Mass spectrometers, separations, software, reagents


Deamidation (+1 Da)
Oxidation (+16 Da)
Disulfide bond scrambling
Sequence truncation
Change in glycosylation
Low abundance host cell proteins
Low abundance sequence variants
Aggregation, protein complex
Drug Antibody Ratio's
Linker measurements
Bound vs unbound drug etc

MS Tools for Major Biopharma Characterization Workflows

Thermo Scientific™ Q Exactive™ MS Family



For all the routine characterization workflows:
intact/top-down, bottom-up, glycan, etc. qualitative and quantitative.



BioPharma Finder™ 1.0
Mass Informatics Platform for Protein Characterization



ProSightPC™ 3.0
Software for Precise Proteomics

Thermo Scientific™ Exactive™ Plus EMR MS



Native MS to analyze large protein complex while preserving non-covalent interactions: antibody-antigen complex, ADCs, antibody mixtures, etc.



BioPharma Finder™ 1.0
Mass Informatics Platform for Protein Characterization

Thermo Scientific™ Orbitrap Fusion™ Tribrid™ MS Family



From routine to the most challenging tasks. The most advanced technology that provides the most comprehensive solutions.




BioPharma Finder™ 1.0
Mass Informatics Platform for Protein Characterization





ProSightPC™ 3.0
Software for Precise Proteomics

The Orbitrap™ in Hybrid and Non-Hybrid Systems




The Orbitrap Principle



FT

frequency



m/z

The Thermo Scientific™ Vanquish™ UHPLC System... A Perfect Front-end!



Vanquish Platform

- Improved retention time precision
- Biocompatible by default
- Increased sample capacity
- Intelligent sample Pre-compression
- Improved sample cooling
- Multiple heating modes
- Active and passive pre-heating
- 4 Detection options
- Enhanced LC/MS control with Sii and Chromeleon
- Viper™-based, tool-free fluidic connections



Vanquish

- 1500 bar compatible system
- Binary pump (HPG)
- Ultra low Gradient Delay Volume


Separations based on power

Vanquish Flex

- 1000 bar compatible system
- Quaternary pump (LPG)
- Medium Gradient Delay Volume


Separations based on chemistry

Antibody Characterization Roadmap




Agenda

Major Characterization Workflows



Intact mass Analysis




Output

- Confident deconvoluted molecule weight.
- Identify glycoforms using the intact mass.
- Identify Antibody Drug Conjugates (ADC).

BioPharma Finder™ 1.0

One software package for

- Protein Sequence Management
- Peptide Mapping
- Intact Analysis



BPF 1.0 – Protein Sequence Manager


Protein Sequence Manager

Saves time

- Starting point for the software.
 - Database for storing protein sequences similar to Proteome Discoverer.
 - Both peptide mapping and intact analysis workflow choose protein sequence from this central location.

Easy to use

- Import FASTA file or paste the sequence into a text box.
 - Define multiple chains (e.g. two light chains, two heavy chains).
 - Define disulfide bonds (information used for intact analysis)
 - Choose fixed modifications
 - Select variable modifications and list of possible glycosylation structures.
 - User definable default modification list.




BPF 1.0 – Intact Protein Analysis

Intact Protein Analysis

- Determine profiles of intact masses
- Automated processing, simplified results and improved quantitation
- Sliding window algorithm for improved ADC analyses and complex data sets
- Target protein sequence matching – identifies n-linked glycosylations and other common modifications.
- **Native MS**
- Ion trap support (ReSpect™ deconvolution only)


Sliding Window Deconvolution

- Produces a single deconvoluted spectrum of all components in the sample regardless of elution time or profile
- Eliminates the need for the user to define the source spectra for deconvolution.
- Works for both simple and highly complex protein mixtures
- Removes the challenges of chromatographic peak picking
- Works with Xtract™ and ReSpect deconvolution




Intact Protein Analysis

Fast Glycan Analysis of Rituximab with MSPac DS-10 Desalting Cartridge






Download Application Note 21465: Fast online desalting of mAbs using a reversed phase desalting cartridge for LC-MS analysis

- A fast 4 minutes desalting method for high throughput glycan characterization.
- Intact mass and the relative glycoform abundance of a mAb within 5 minutes.
- In-depth characterization for glycoforms detection below 1% relative intensity.
- Broadly applicable to other mAbs and similar biopharmaceutical compounds.




MS of Intact Lysine-linked ADC




Separation of ADC


by Reversed Phase
for direct coupling with MS



by Hydrophobic Interaction (HIC)



MS of Intact Cysteine-linked ADC



Cysteine linked ADC requires native MS for intact analysis


Native MS using Exactive Plus EMR

Performing native MS

- An ESI compatible **volatile solution with near neutral pH** is used to prepare protein samples.
e.g. 50 mM ammonium acetate pH 6.9
- Under these conditions, the ionized proteins carry fewer charges than those produced by ESI in acidic, denatured condition.
- Therefore, **in native MS, protein ions are detected at a significantly higher m/z range (>5000 -10,000 m/z for antibody complexes)** than conventional MS in acidic condition.


Exactive Plus EMR

- Extended mass range up to m/z 20,000
- Unmatched Desolvation using in-source CID and in HCD cell
- Improved high mass transmission for large protein assemblies




Native MS of an ADC Brentuximab Vedotin

Raw spectrum



Exactive Plus EMR,
35K


Deconvoluted spectrum




$$\overline{DAR} = \frac{\sum_0^8 nA_{DAR_n}}{\sum_0^8 A_{DAR_n}} = 4.2$$

Agenda




Major Characterization Workflows



Reduced Rituximab



Rapid Subdomain Analysis of NIST mAb




Xtract™ deconvolution

Matched Sequence	Matched Delta Mass (ppm)	Relative Abundance
Fd	1.05	100.0000
LC	2.50	86.4514
Fc;1xA2G1F	2.34	34.9027
Fc;1xA2G0F	2.47	34.8168
Fc;1xA2G2F	2.48	3.6534

Agenda


Major Characterization Workflows




Top-Down Sequencing

Main parameters that can be controlled for ETD fragmentation on an Orbitrap Fusion mass spectrometer

- Isolation window




- AGC target for precursor ions and reagent
- Reaction time
- Supplemental energy



Top-Down sequencing

Light Chain of Trastuzumab



ETD settings: 300 Da isolation window, 3E5 precursor, 7E5 reagent, 10 ms reaction time



Due to the complexity of the spectra in top-down analysis, high resolution is required

Top-Down Sequencing

Deconvolution



Matching

Precursor Mass

Type: Monoisotopic
Observed: 23,428.53
Theoretical: 23,428.52
Mass Diff. (Da): 0.001
Mass Diff. (ppm): 0.06


% Fragments Expl... 23 %
% Residue Cleava... 48 %

N D I Q M T Q S P S S L S A S V G D R V T I T C R A 25
26 S Q D V N T A V A W Y Q Q K P G K A P K L L I Y S 50
51 A S F L Y S G V P S R F S G S R S G T D F T L T I 75
76 S S L Q P E D F A T Y Y C Q Q H Y T T P P T F G Q 100
101 G T K V E I K R T V A A P S V F I F P P S D E Q L 125
126 K S G T A S V V C L L N N F Y P R E A L K V Q W K V 150
151 D N A L L Q S G N S Q E S V T E Q D S K D S T Y S L 175
176 S S S T L T L S K A D Y E K H K V Y A C E V T H Q G 200
201 L L S S P V T K S F N R G E C


Top-Down sequencing

High sequence coverage for the light chain, Fc and Fd were obtained from the combined ETD and EThcD experiments.


Light Chain



Fc



Fd



Improved Coverage For Top Down IgG Analysis

Light Chain (LC)

N D V L M T Q T P L I S L P V S I G D Q A S I S C R S 25
26 S Q Y I V H S N G N T Y L E W Y L Q K P G Q S P K 50
51 L L I Y K V S N R F S G V P D R F S G S G S G T D 75
76 F T L K I S R L E G Y F Q G S H V P 100
101 L T F G A G T I K A D A A P I V S I F P P 125
126 S S E Q L T S C S V L C F L N N F P K D I N 150
151 V K W K I D G S E R Q N G V L N S W T D Q D S K D 175
176 S T Y S M S S T L L T L K D E Y E R H N S Y T C E 200
201 A T H K L T S T S P I V K S F N R N E C

Heavy Chain (HC)

N Q V Q L I K E I S G P G L V A P S Q S L I S I T C T V S 25
27 G F S L L L G Y G V N W V R Q P P G Q G L E W L M G 50
51 I W G D G S T D Y N S A L K S I R I S I T K D I N S K 75
76 S I Q V F I K M N S L Q T D D T A A K Y Y C T R A P Y 100
101 G K Q Y F A Y W G Q G T L V T V S A A K T T P P S 125
126 V Y P L A P G S A A Q T D S M V T L G C L V K G Y 150
151 F P E P V T V T W N S G S L S G S V H T F P A V L 175
176 Q S D L Y T I S S V I S T W P S E T V T C 200
201 N I V A H P A S T K V K V P R D C G C K P C 225
226 I L C T V P E S V F I F P P I K O V L T I T L 250
251 T P K V T C I V D K D I P E Y Q F S W F V D 275
276 D I V E V H T A H T Q P R E E Q F N S T F R S V S E 300
301 L L P I M H Q D W L I N G K E F K C R V N S A A F P A 325
326 P I E K L I S K T K G R P K A P Q V Y T I P P P K 350
351 E Q M A L K D K V S L T C M I T D F F P E D I T V L E 375
371 W Q W N G Q P A L E N Y K N T Q P L I M D T D G S Y F 400
401 V Y S K L I N V Q K S N W E A G N T F L T C S V L L H E 425
421 G L H N H H T E K S L S H S P G C

cz by

91%

63%

Comprehensive Sequence Map

- Reduced IgG, infusion at 3 μ l/min
- Individual charges states of both proteins were isolated and fragmented with CID, ETD and HCD
- 240,000 resolution
- Improved sequence coverage with Advanced Vacuum Technology and ETD HD

	OT FUSION	OTF LUMOS	GAIN
LC	77%	91%	18%
HC	46%	63%	37%

Acknowledgements

North America

- Stephane Houel
- Terry Zhang
- Aaron Bailey
- Michael Blank
- Jonathan Josephs

North America

- Jennifer Sutton
- Seema Sharma
- David Horn
- Shanhua Lin
- Mark Sanders
- Ken Miller

Europe

- Martin Samonig
- Kai Scheffler
- Yue Xuan
- Eugen Damoc
- Remco Swart

